For the quarter ending 2025-09-30, IMRX had $201,207,579 increase in cash & cash equivalents over the period. -$11,984,490 in free cash flow.
| Cash Flow | 2025-09-30 | 2025-06-30 |
|---|---|---|
| Program expenses-IMM1104 | -23,946,023 | - |
| Program expenses-IMM6415 | -4,097,651 | - |
| Program expenses-Other Programs | -6,509,028 | - |
| Non-program expenses | -7,464,608 | - |
| Employee-related costs | -25,539,568 | - |
| Stock-based compensation expense | -7,890,500 | - |
| Depreciation and amortization | -418,416 | - |
| Other segment items | 1,940,894 | - |
| Net loss | -14,964,876 | -29,480,012 |
| Depreciation and amortization expense | 78,840 | 169,788 |
| Reduction in carrying amount of right-of-use assets | 87,274 | 168,386 |
| Intangible asset amortization | 7,317 | 14,633 |
| Stock-based compensation expense | 1,456,080 | 3,217,210 |
| Net accretion of discount on marketable securities | 0 | 0 |
| Loss on disposal of fixed assets | 0 | - |
| Prepaid expenses and other current assets | 168,824 | -2,072,921 |
| Other assets | -348,790 | -454,058 |
| Accounts payable | -974,893 | 500,679 |
| Accrued expenses | 2,366,906 | -458,170 |
| Lease liabilities | -84,230 | -162,298 |
| Other liabilities | -129,619 | -23,957 |
| Net cash used in operating activities | -11,977,235 | -23,526,762 |
| Purchases of property and equipment | 7,255 | 11,061 |
| Purchases of marketable securities | 0 | - |
| Maturities of marketable securities | 0 | 0 |
| Net cash (used in) provided by investing activities | -7,255 | -11,061 |
| Proceeds from exercise of stock options | 136,645 | 2,055 |
| Proceeds from issuance of common stock under employee stock purchase plan | 288,018 | 133,892 |
| Proceeds from issuance of common stock under at-the-market offering, net of issuance costs-At Market Offering | 15,020,046 | - |
| Proceeds from issuance of common stock under at-the-market offering, net of issuance costs-Warrant | 24,998,919 | - |
| Proceeds from issuance of common stock under at-the-market offering, net of issuance costs-Public Offering | 164,500,006 | - |
| Proceeds from issuance of common stock under at-the-market offering, net of offering expenses | - | 13,676,667 |
| Proceeds from issuance of common stock through private placement with aventis inc | 25,000,000 | - |
| Payment of offering and placement costs | 3,074,898 | 64,013 |
| Net cash provided by financing activities | 213,192,069 | 13,748,601 |
| Net increase (decrease) in cash and cash equivalents | 201,207,579 | -9,789,222 |
| Cash and cash equivalents at beginning of period | 36,144,720 | - |
| Cash and cash equivalents at end of period | 227,563,077 | - |
Immuneering Corp (IMRX)
Immuneering Corp (IMRX)